Work

214eTiP A prospective, multicenter phase II study of ctDNA-guided Individualized therapy with aumolertinib ± chemotherapy in advanced L858R EGFR+ NSCLC

Year: 2026

Type: article

Abstract: The third-generation EGFR-TKI aumolertinib has shown significant efficacy and favorable safety in NSCLC patients with EGFR-sensitive mutations. Despite the high response rates to third-generation EGFR-TKIs, patients with the exon 21 L858R mutation typically have a poorer prognosis compared to those with exon 19 deletions, based on tumor biology and previous clinical data, warranting exploration of intensified individualized treatment strategies.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106521

Authors: H.J. Feng, G. Jin

Institutions: Shanxi Medical University, Second Hospital of Shanxi Medical University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910